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Abstract (79 words): 
Advances in transgenic and gene-targeted mice have enabled tissue and cell-
specific investigation of skeletal regeneration.  While genetically modified animals 
offer incredible insights into the temporal and spatial importance of various 
molecules, the complexity and rapidity of healing renders studies of regenerative 
biology challenging. Herein, cells and extracellular mediators that play a key role 
in bone healing are reviewed.   We will focus on recent studies that explore the 
origins and fates of various cells in the fracture environment. 
 
Abstract 
The biology of bone healing is a rapidly developing science. Advances in transgenic and 
gene-targeted mice have enabled tissue and cell-specific investigations of skeletal 
regeneration. As an example, only recently has it been recognized that chondrocytes 
convert to osteoblasts during healing bone, and only several years prior, seminal 
publications reported definitively that the primary tissues contributing bone forming cells 
during regeneration were the periosteum and endosteum. While genetically modified 
animals offer incredible insights into the temporal and spatial importance of various gene 
products, the complexity and rapidity of healing—coupled with the heterogeneity of 
animal models—renders studies of regenerative biology challenging. Herein, cells that 
play a key role in bone healing will be reviewed and extracellular mediators regulating 
their behavior discussed.  We will focus on recent studies that explore novel roles of 
inflammation in bone healing, and the origins and fates of various cells in the fracture 
environment.   
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Introduction 
Injuries to the appendicular skeleton heal through two distinct processes: direct (primary) 
or indirect (secondary) healing. Primary healing involves a direct transition of 
mesenchymal cells to bone-forming osteoblasts (intramembranous ossification). 
Secondary healing progresses through a cartilage intermediate before bone is formed by 
osteoblasts (endochondral ossification). The cellular and molecular factors that 
coordinate fracture callus formation and resolution are complex and highly orchestrated. 
This review will primarily discuss secondary healing, since the vast majority of fractures 
that occur clinically heal in this manner. 
 
The process of bone healing has a variety of cellular components required for the 
progression of healing (Figure 1). Inflammatory cells (i.e., T-cells, B-cells, mast cells, 
macrophages, eosinophils, and neutrophils) are the initial cellular component of the 
fracture environment, followed by mesenchymal progenitor cells, endothelial cells, 
chondrocytes, osteoblasts, and finally osteoclasts. The process of fracture healing can be 
easily considered in discrete temporal segments; however, it is important to recognize 
that there is significant overlap of the temporal segments of healing, and associated cell-
types coexist. This is an important concept to consider, because cell-to-cell signaling, in a 
heterotypic manner (across cell-types) is undoubtedly important. For example, both 
chondrocytes and osteoblasts can promote blood vessel in-growth through their 
production of vascular endothelial growth factor (VEGF) (1). Conversely, endothelial cells 
promote bone formation through production of bone morphogenetic protein (BMP) and 
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new data suggest that vasculature guides the formation of a cartilaginous template and 
stimulates conversion of hypertrophic chondrocytes to osteoblasts (2). 
 
For this review we will consider the cells of fracture in a well-described and useful 
temporal sequence, familiar to many in the field. Where appropriate, we will discuss 
signaling factors regulating or produced by those cells, and in some cases consider signal 
transduction cascades and molecular programs that guide cellular physiology. While this 
review is not expected to be a comprehensive treatise on all known signaling factors, nor 
all known transcriptional regulators, we hope to present a detailed examination of the 
cells involved in bone regeneration. 
  
Inflammatory Phase – Inflammatory Cells 
 
Acute Inflammation 
The acute pro-inflammatory response is essential for initiating fracture healing (Figure 
1B,C and 2). After fracture, bone architecture and vascular supply are disrupted (Figure 
1A). This results in a loss of mechanical stability, a decrease in tissue oxygenation and 
nutrient supply, and the release of bioactive factors at the site of injury (3, 4). The 
inflammatory cells themselves, along with the cytokines and extracellular matrix they 
produce, appear essential in facilitating normal healing, as mice deficient in innate and 
adaptive immunity have significantly impaired endochondral bone repair (5).  
 
Within the first minutes of fracture, a fibrin-rich blood clot forms to achieve hemostasis 
(Figure 1B). The role of this fibrin-rich clot during fracture healing has been examined in 
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mice lacking the key enzyme for fibrin degradation, plasminogen. While fibrin is not 
required for bone healing, repair does not properly progress without fibrinolysis. 
Specifically, the absence of plasminogen results in ectopic ossification and poor healing 
(6)
.  
 
Cytokines released by the clot (particularly during platelet degranulation) recruit 
inflammatory cells including lymphocytes, macrophages, eosinophils, and neutrophils (3, 
4, 7, 8)
. As one example, C-C Motif Chemokine Ligand 2 (CCL2) (also known as 
Monocyte Chemoattractant Protein-1) (CCL2 or MCP1) and its receptor Chemokine 
Receptor type 2 (CCR2) stimulate monocyte chemotaxis in the inflammatory response (9). 
CCL2 is expressed from days 1-3 in the fracture site (10). When subject to fracture, Ccl2-
null and Ccr2-null mice both exhibit delayed fracture healing and decreased callus 
volume as a result of diminished mesenchymal cell infiltration and impaired 
vascularization (10, 11).  
 
Inflammatory cells are deposited throughout the clot during hemorrhage and migrate to 
the injury site from local sources. While, the contribution of inflammatory cells derived 
from circulation versus those that are locally derived is not fully-understood, tissue 
resident macrophages, called ostealmacs, are necessary for fracture healing. One role of 
inflammatory cells, particularly neutrophils and macrophages, is debridement of injured 
and devitalized tissue. Inflammatory cells also produce cytokines that positively and 
negatively influence healing (12-14) (Table S-1). Some of these cytokines are detected at 
the fracture site within the first 24 hours post-injury and are important for the expansion 
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of the inflammatory response by acting on cells in the bone marrow, periosteum, and 
hematoma (15, 16).  
 
Macrophages secrete the pro-inflammatory molecule Interleukin 1 (IL1). IL1 in-turn 
regulates expression of cyclooxygenases (Cox1 and Cox2), which are the enzymes that 
synthesize prostaglandins in injured tissues (17). Non-steroidal anti-inflammatory drugs, 
which inhibit cyclooxygenase activity, cause delays in fracture healing (14, 18-22). These 
delays have been attributed to inhibition of Cox2 activity during fracture healing (14, 15, 23, 
24)
. Interestingly, marrow stromal cells derived from Cox2-null mice have diminished 
ability to form bone nodules in vitro, and this deficiency can be alleviated by the addition 
of prostaglandins to the culture media (15). However, eliminating signaling through IL1-
beta does not appear to affect fracture repair (25). 
 
Other pro-inflammatory factors are also essential for fracture healing. For example, mice 
lacking the gene that encodes the Tumor Necrosis Factor alpha (TNF-alpha) receptor 
have a substantial delay in the onset of chondrocyte differentiation (26), and a delay in 
endochondral ossification (12). Interleukin 6 (IL6) has also been implicated in bone 
healing. Genetic ablation of IL6 in mice disrupts healing due to delayed callus 
mineralization, maturation, and conversion to bone (27). Early fracture healing in IL6-null 
mice is marked by decreases in osteocytes and callus strength (28). In addition to 
providing inflammatory cytokines, inflammatory cells also produce growth factors such 
as Fibroblast Growth Factors (FGF), Platelet-Derived Growth Factor (PDGF) and 
Transforming Growth Factor beta (TGF-beta), which initiate the repair process by 
Au
tho
r M
an
us
cri
pt
facilitating proliferation and differentiation of the stem cells that give rise to the fracture 
callus (4, 29, 30). 
  
The multifactorial role of the acute pro-inflammatory response together contributes to its 
significance in healing and inhibition of inflammation is associated with delays in 
fracture repair (14, 18-22, 31). For example, depletion of macrophages during the early phases 
of fracture repair has been shown to reduce both callus size and chondrogenesis resulting 
in impaired fracture union (32, 33). Defects in fracture healing can also be seen in mice 
lacking macrophage migration inhibitory factor (MIF) (34). While endochondral bone 
regeneration is the primary mechanism of fracture repair, depletion of macrophages also 
impacts osteogenesis during intramembranous healing (35).  Similarly, the absence of T 
and B lymphocytes and neutrophils also alters fracture healing (36-38).  
 
The role of complement factors in healing has been investigated by Igantius and 
colleagues. Their work has demonstrated that mice deficient in C5, but not C3, show 
reduced bone healing. Interestingly, C5a activation is independent of C3 (39).  
Furthermore, recent work demonstrates that both C5a receptors, C5aR1 and C5aR2, are 
required for bone healing, particularly in cartilage-to-bone transition (40). Interestingly, 
this is in contrast to C5aR antagonists in polytrauma fracture healing, which has been 
shown to improve bone healing (41). As many cell types involved in bone healing express 
complement receptors, including, inflammatory cells, osteoclasts, and osteoblasts, fully 
understanding the role of complement in bone healing will require temporal and cell-type 
specific allelic disruption.  
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Resolving Inflammation 
While the inflammatory phase of fracture healing begins during the earliest stages of 
repair, current evidence indicates that the inflammatory cells are also present throughout 
later phases and appear to undergo changes as healing proceeds (reviewed in: (42)). 
Analysis of fracture healing in mice lacking the TNF-alpha receptor reveals delays not 
only during acute inflammation, but in later stages of healing as well (12, 26). Likewise, IL6 
expression appears bimodal during fracture healing suggesting a temporally specific role 
for inflammatory cytokines during bone repair (43).  
 
Changes in macrophage phenotype may explain this dual role in fracture healing. 
Macrophages can polarize along a continuum of pro- to anti-inflammatory states (Figure 
3). In the first few days post injury, pro-inflammatory macrophages are produced by 
“classical activation” that is typified by the innate immune response to bacterial 
pathogens and tissue injury through toll-like receptors (TLR). Classically activated 
macrophages (CAMs) are primed by exposure to interferon-gamma (IFN-gamma). 
Thereafter, pathogen-associated molecular pattern binding to TLR-family receptors on 
CAMs up-regulates the pro-inflammatory cytokines TNF-alpha, IL1 and IL6 through the 
NFκB pathway. Recent work from the Goodman laboratory has shown that CAMs 
indirectly promote osteogenesis by regulating MSC, albeit these studies have not been 
supported by in vivo studies (44). 
 
Once macrophages have debrided the wound and are no longer classically activated, they 
can assume an anti-inflammatory state. Anti-inflammatory macrophages, also known as 
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alternatively activated macrophages (AAMs), are generated through IL4 and IL13 
signaling. In contrast to CAMs, alternative polarization of macrophages results in cellular 
activity that promotes collagen deposition and the return to tissue homeostasis. 
Production of TGF-beta, IL10 and arginase, as well as other secreted anti-inflammatory 
proteins, is associated with the repair of tissues following infectious and traumatic insults 
(45, 46)
.  
 
Chronic Inflammation 
Chronic, non-resolving inflammation is detrimental to fracture healing. Experimental 
evidence indicates fracture healing and osseointegration are disrupted in conditions where 
there is chronic, non-resolving inflammation, such as diabetes (47-49). Elevated TNF-alpha 
signaling may underlie some chronic inflammatory conditions (49), and evidence suggests 
blocking this pathway may have a therapeutic benefit in fracture healing (50).  
 
Aging is also associated with a non-resolving inflammatory state and impaired bone 
healing (16, 51-54). In elderly animals, there are alterations to both progenitor and 
inflammatory cells (55). In particular, macrophages exhibit significant age-related 
alterations in function that change the inflammatory environment of aged animals and 
impact healing (reviewed in: (56)). Cutaneous wound healing is delayed in aged mice; 
however, these delays can be overcome by grafting macrophages derived from younger 
animals (57). Similarly, rejuvenation of the inflammatory system in aged animals 
significantly accelerates fracture repair (53, 58, 59). Thus, the functional capacity of juvenile 
macrophages appears to be more beneficial for healing than that of elderly macrophages. 
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Compared to young mice, the innate and adaptive immunity cells of aged mice are more 
highly enriched during fracture healing (60). Bone regeneration is inhibited by increased 
CD8+ T cells which produce interferon-gamma and TNF-alpha and increased expression 
of CXCL8, CXCL9, and CXCL5 cytokines. The specific contribution of CD8+ T cells on 
fracture healing was demonstrated in a murine osteotomy model (61). Depletion of CD8+ 
T cells improved callus formation and bone mineral density. Conversely, increasing the 
CD8+ T cell population using adaptive transfer resulted in delayed callus formation and 
decreased bone mineral density. This work supports CD8+ T cell number as a potential 
prognostic marker for bone healing. Contrary to CD8+ T cells, IL-17A producing gamma 
delta T cells are essential for fracture repair. Loss of IL-17A disrupts proliferation and 
differentiation of MSCs resulting in delayed callus formation and lower bone mineral 
density (62).  
 
The cellular mechanisms causing dysregulation of immune cell function in aged animals 
is still being investigated. However, age-related changes to the macrophages appear to 
alter production of inflammatory cytokines. For example, decreases in Cox2 expression, 
an enzyme required for prostaglandin production, were observed during fracture healing 
in aged mice, and age-related delays were mitigated by activation of the prostaglandin 
receptor (54). Ultimately, understanding the altered functional characteristics of the 
macrophages may be essential for addressing the decreased healing in the elderly (63); 
however, it is also important to consider that there are other non-inflammatory cell-
autonomous explanations for altered healing with aging and metabolic conditions, such as 
reductions in progenitor cell number and function (64). 
Au
tho
r M
an
us
cri
pt
Fibrovascular Phase - Endothelial and Mesenchymal Progenitors Cells 
Following inflammation, the angio-mesenchymal phase of repair begins (Figure 1D and 
2A). This phase has been termed the “fibrovascular phase” and is defined by vascular 
remodeling (angiogenesis and neovascularization) and recruitment of mesenchymal 
progenitor cells, sometimes referred to as mesenchymal stem cells (MSCs), that will 
ultimately differentiate into chondrocytes and osteoblasts to regenerate the fractured 
bone.  
 
Revascularization 
During the initial fracture trauma, the periosteal, cortical, and medullary vascular supply 
are disrupted leading to acute cellular necrosis and acidosis. The lack of vascularization 
causes local hypoxia, in which oxygen tension is lowered to 0.1-2% (65-67) from 5%. 
Revascularization is required for perfusion of the callus with oxygen, nutrients, 
inflammatory and progenitor cells to facilitate repair, and the egress of waste products. In 
most cases, vascular supply is reestablished rapidly through the development of a new 
vascular network (68).  
 
Formation of the network occurs by two distinct processes: angiogenesis and 
vasculogenesis. Angiogenesis is the process by which new blood vessels are formed by 
sprouting from existing vasculature. Vasculogenesis is de novo formation of blood 
vessels from in situ endothelial progenitor cells (EPCs) within the callus. Endothelial 
cells in forming callus vasculature can develop from a variety of sources, including, 
existing vessels of the periosteum and the intramedullary vasculature (69); circulating 
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EPCs (70) that are increased during fracture repair (71); or the bone marrow (72). Circulating 
EPCs are not only increased in rodent models, but are significantly increased in human 
patients at day three post-fracture (73).  
 
Vascular endothelial growth factor (VEGF) is a well-characterized driver of angiogenesis 
and vasculogenesis (74). VEGF is produced by a variety of cells in the fracture callus, 
including inflammatory cells and mesenchyme, but also osteoblasts and hypertrophic 
chondrocytes.  VEGF binds the VEGF family of receptors VEGFR1 (FLT1) and 
VEGFR2 (FLK1) activating signaling cascades that lead to increased proliferation and 
sprouting of endothelial cells, and recruitment of EPCs to the fracture. In a model of 
distraction osteogenesis, blockade of VEGF activity via antibodies to VEGFR1 and 
VEGFR2 results in decreased vessel volume and reduction of callus formation (75). 
Neutralization of VEGF by the soluble VEGF receptor (IgG-Flt) recapitulated this delay 
of callus vascularization (76).  
 
VEGF is a classical downstream target gene of hypoxia inducible factor 1-alpha (HIF1-
alpha), which is stabilized in hypoxic (77) and other conditions including when lacate 
levels are increased, as they are after fracture (67). Induction of HIF1-alpha and VEGF 
protein production peak at day 10 post-fracture in mice, during the period of 
endochondral ossification (2, 78). Mice with increased expression of HIF1-alpha develop 
hyper-vascularized long bones with enhanced healing (79). On the other hand, HIF1alpha-
null mice (80), and mice with HIF1-alpha disrupted in osteoblasts (1), have delayed callus 
formation in fracture healing.  
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One interesting aspect of VEGF signaling is that during endochondral ossification, VEGF 
protein binds to the cartilage matrix until liberated by matrix metalloproteases (MMPs). 
MMPs are a family of extracellular proteases that degrade and remodel the extracellular 
matrix during development and repair. MMPs-2, -9, and -13 are robustly expressed 
during fracture repair and their absence results in impaired healing (13, 81-84). While the 
Mmp2-null mutation delays only bone remodeling, the Mmp9- and Mmp13-null 
mutations affect bone formation by altering cartilage remodeling and vascularization. 
Importantly, administration of rVEGF to Mmp9-null mice during fracture healing rescues 
the null phenotype, indicating that VEGF release from the matrix by MMP9 is required 
for angiogenesis. MMP9 regulates VEGF availability.  
 
The extracellular matrix (ECM) can also influence the angiogenic response to fracture 
healing. For example, thrombospondins (TSP) are a family of non-fibrillar matricellular 
proteins with a potent anti-angiogenic function (85). Tsp2-null mice exhibit increased 
angiogenesis in the fracture callus (86, 87), resulting in enhanced ischemic bone healing and 
alterations in callus composition in non-ischemic conditions. As such, targeting this 
pathway is an attractive therapeutic target for enhancing vascularity in bone regeneration. 
Osteopontin is also a modulator of fracture vascularization. Mice deficient in osteopontin 
show delayed angiogenesis and smaller calluses (88). Cell-type specific deletion of TSP2 
and osteopontin using Cre-LoxP has not been described but would serve to better 
elucidate the mechanistic bases for these observations.  
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As the angiogenic response is a required event in fracture healing, deficiencies in 
angiogenesis result in delayed or insufficient fracture repair. Clinically, the non- or 
delayed-union rate increases from a basal level of 10-20% in the normal fracture 
population, to 46% when there is concomitant damage to the vasculature (89). Multiple 
preclinical models have been used to investigate the underlying mechanisms for this 
defect in healing. In experimental models of ischemia, fracture healing is significantly 
altered due to massive apoptosis of the periosteum (90). Similarly, de-vascularization of 
the periosteum proximal to the fracture site results in delayed healing and inhibits new 
bone formation (91). Some of the negative effects of ischemic bone fractures can be 
mitigated by environmental hyperoxia. In an experimental model of an ischemic tibia 
fracture, mice in hyperoxic conditions (50% environmental oxygen) demonstrated an 
increase in callus volume and cartilage content (67). The mice also were less likely to 
progress to non-union. 
 
Co-morbidities such as aging, diabetes and smoking are also associated with delayed 
fracture healing, likely due to underlying vascular defects. Elderly and middle aged mice 
exhibit a decreased callus volume formation coupled with inhibited angiogenesis, and 
reduced expression of VEGF and MMP9 relative to juvenile fractures (92). In an obesity-
induced model of type II diabetes mellitus, neovascularization of the fracture callus is 
inhibited resulting in decreased formation of woven bone (93). In distraction osteogenesis, 
cigarette smoking inhibits neovascularization and delayed tibial lengthening (94). Taken 
together, identifying clinically relevant conditions that affect angiogenesis are required to 
improve outcomes in fracture healing.  
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Mesenchymal progenitor cells 
The other primary cellular component of the fibrovascular callus, is the mesenchymal 
progenitor cell (MSC).  MSCs are multipotent cells that give rise to osteoblasts, 
chondrocytes, fibroblasts, myocytes and adipocytes (95). While these cells are referred to 
as ‘stem cells’, it is notable that in most cases, criteria of stemness are not well-
established for these cells. Even within the MSC population, sub-populations have been 
identified that differ in lineage potential and function. Nestin, an intermediate filament 
fiber, has been used to differentiate between populations of MSCs that are mesodermal- 
or neural crest-derived. Nestin-negative MSCs primarily contribute to skeletogenesis in 
the fetus whereas nestin-positive cells assume this role later in life (96). In bone fracture 
repair, quiescent MSCs reprise their developmental role as osteochondral progenitor cells 
(Figure 1, 2, and 4).  
 
The majority of MSCs recruited to the fracture site are derived locally from the 
periosteum and bone marrow. The original experimental evidence for this came from 
Colnot who used lineage analysis to demonstrate that locally derived progenitors from the 
periosteum, endosteum, and bone marrow are the major cellular contributors to the 
fracture callus (97). Subsequently, using the mesenchymal marker α-Smooth Muscle 
Actin-9 (α-SMA9), Cre-recombination based fate mapping shows α-SMA9+ cells invade 
the fracture site from the periosteum 2-days post fracture, and by 6 days post fracture this 
α-SMA9+ population has robustly expanded to provide a large source of osteocyte 
progenitors (98, 99). Gremlin-CreERT2 and LepR-Cre cells have also been shown to give 
rise to osteoblasts and chondrocytes in the fracture callus (100, 101). Table S-2 provides a 
Au
tho
r M
an
us
cri
pt
summary of recent investigations in bone healing that employed Cre systems and 
includes additional Cre mice relevant to fracture biology that have yet to be studied. 
Together, these various Cre mice will be useful for better defining the spatial and 
temporal regulation of cells contributing to bone healing.  
 
Recruitment of MSCs in the fracture repair program is under molecular regulation by 
cytokines released at the fracture site, particularly CXCL12, also known as stromal cell-
derived factor 1 (SDF1).  SDF1 is released by the injured periosteum and drives 
mobilization and homing of MSCs through CXCR4 (102). Partial disruption of 
SDF1/CXCR4 in mouse allografts lead to decreased MSC chemotaxis and bone 
formation.  In a live bone graft model of repair, both antibody sequestering of SDF1 and 
pharmacologic inhibition of its receptor CXCR4 resulted in inhibited MSC chemotaxis 
and decreased formation of bone in the callus (102). SDF1 is under transcriptional 
regulation by HIF1-alpha in response to ischemia (103), demonstrating a role for the 
hypoxic condition of the fracture environment in directing MSC recruitment, as well as 
vascularization.  In a tibial fracture model in mice, SDF1 increased callus formation as 
well as induced expression of VEGF and Runx2 in the soft tissue callus, indicative of 
increased angiogenesis and osteogenesis (104). Recently, implantation of bone marrow 
derived MSCs (BM-MSCs) overexpressing SDF1 in a bone defect model resulted in 
improved new bone formation relative to BM-MSC implantation alone (105). It is notable 
that the SDF1/CXCR4 homing pathway is also required for EPC recruitment in tibial 
fracture healing. Cxcr4-null mice exhibit decreased callus formation as a result of 
inhibited EPC recruitment, decreased blood flow in the fracture site, and decreased 
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VEGF and CD31 (an endothelial cell marker) expression in the callus one week post 
fracture (106). Exogenous SDF-1 was not sufficient to rescue this phenotype, indicating an 
exclusive requirement of CXCR4 in SDF-1 stimulated EPC recruitment.  
 
Notch signaling is another potentially important factor in both regulating MSC number 
and activation. Mice with Notch signaling disrupted through Mx1-Cre mediated 
overexpression of the dominant negative mastermind (DnMAML) show alterations in 
callus size (38).  Mice with complete disruption of canonical Notch signaling by Prx1-Cre 
mediated disruption of the Notch transcription factor CSL have non-unions. Notch 
signaling appears to be required for the proliferation and/or migration of mesenchymal 
progenitor cells (107).  
 
While the data using reporter mice support the concept that MSC in fracture callus are 
derived from periosteal and endosteal activation, there is still some potential that MSC 
could be derived from the circulation. Using CMV-Cre-R26R-LacZ-MSCs transplanted 
into a fractured mouse, it was shown that MSCs in circulation localize in the endosteum, 
but not periosteum, of the fracture site as early as 3 days post injury (108). To study if 
circulatory MSCs could contribute to fracture healing, BMP-2-Lac-Z-MSCs were 
transplanted which demonstrated BMP-2 expression in the endosteum. However, it is still 
unclear if MSCs in circulation contribute significantly to bone remodeling by 
differentiating into chondrocytes and osteoblasts or if they promote healing indirectly in a 
paracrine fashion through the release of growth factors and cytokines. 
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Bone Formation – osteoblasts and chondrocytes 
Following the fibrovascular phase of healing, many of the MSC that formed the fibrovascular 
callus undergo differentiation to either osteoblasts or chondrocytes to initiate the bone 
formation phase of healing (98) (Figure 1E, Figure 2, 4).  
 
Differentiation of MSCs into bi-potential osteochondral progenitor cells is initially regulated 
by Sox9 (109). Sox9 is required for chondrogenesis and genetic disruption studies demonstrate 
that absence of this transcription factor leads to the complete elimination of the cartilaginous 
anlagen in the developing skeleton (110). Conversely, in osteoblasts, downregulation of Sox9 
in bi-potential cells releases repression of Runx2 (111). Runx2 deletion results in a complete 
loss of osteoblasts in mouse embryos (112-114). However, disruption of Runx2 in chondrocytes 
is embryonic lethal and inhibits endochondral ossification (115). While Runx2 has been 
traditionally called a ‘master regulator’ of osteoblastogenesis, it may play a larger upstream 
role as a regulator of bi-potential osteochondral progenitor cells. Runx2 transcriptionally 
regulates osteoblastogenesis in part through the transcription factor Sp7 (Osterix) (114, 116). 
Knock-out of Osterix is also associated with lack of osteoblasts, however, Osxterix 
expression is absent following deletion of Runx2, suggesting Osterix is downstream (114, 116). 
Sox9 also actively represses osteogenic potential by suppressing Runx2 (111), thereby these 
opposing programs appear to act as a molecular switch between cartilage and bone fate in 
osteochondral progenitor cells (117).  
 
Factors regulating the decision of progenitor cells towards the chondrogenic or osteogenic 
fate are multifactorial, integrated and still being defined. Extrinsically, mechanical factors 
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and oxygen tension are undoubtedly important variables regulating fate decision (118, 119). 
These microenvironmental cell-extrinsic factors then lead to very specific cell-intrinsic 
regulation of chondrogenesis and osteoblastogenesis. 
 
Increased motion has been shown to induce the formation of more chondrocytes and in-turn 
increases endochondral ossification (118, 120, 121), while stabilization results in the generation of 
more osteoblasts and direct bone repair via intramembranous formation (120). Specifically, 
strains smaller than 5% and hydrostatic pressures less than 0.15MPa promote 
intramembranous formation (121).  Morgan et al. (2010) have assessed strain distribution 
during healing in a loaded osteotomy model and then associated strain patterns with the type 
of bone formation determined histologically (122).  Higher octahedral shear strain and 
maximum principal strain increased cartilage and decreased woven bone, while volumetric 
strain was less reliably associated with intramembranous bone vs a cartilage phenotype.  
 
Another putative environmental signal that may regulate the fate decision of MSC is oxygen 
tension. The relationship between oxygen tension and MSC differentiation in vitro has been 
extensively investigated, and the preponderance of evidence suggests that hypoxia promotes 
a chondrogenic phenotype, whereas higher levels of oxygen promote osteoblast 
differentiation. In vivo, this relationship between oxygen and MSC fate decision has been 
computationally modeled and experimentally validated through directed callus oxygenation 
(123, 124)
. However, other work has demonstrated that reducing inspired oxygen levels leads to 
problems with healing, but does not appear to alter the mode of fracture healing (67).  
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Secreted growth factors also have a direct effect on MSC differentiation.  BMPs are the 
classic osteogenic molecule associated with bone formation.  In vitro BMPs directly 
stimulate MSC osteoblast differentiation and canonical bone programs characterized by 
the activity of the Runx2 and Sp7 (Osterix) transcription factors which are direct, 
downstream targets of BMP signaling (125). In vivo, after trauma, periosteal cells express 
BMP2 and BMP4 and over time they proliferate in response to BMP5 and BMP6 (126, 127). 
Notably, BMPs are also important in dictating chondrocyte differentiation, so that mice 
with conditional disruption of Bmp (in particular Bmp2) show non-unions (128-130). 
Signaling via BMP2 is also absent during intermediate stages of intramembranous repair, 
which is critical for preventing cartilage formation (131). At day 10 post-injury, BMPs 
(2,4,5,6,7,and 8), extracellular BMP antagonists (BMP3 and noggin), BMP receptors 
(1A, 1B, and II), and effectors (p-Smads 1,5, and 8) are not detected in osteoblasts, 
osteoclasts, or the periosteum within a fracture site’s new bone (132). Addition of 
recombinant human BMP2 (rhBMP2) to stabilized fractures results in formation of new 
cartilage primarily at the periosteal surface, which ultimately leads to a callus with 
increased cartilage and total volume, but no increase in intramembranous bone formation 
(131)
. The dual role of BMP signaling in regulating both osteoblast and chondrocyte 
differentiation of multipotent mesenchymal progenitors is not fully understood in the 
context of fracture repair. Presumably, co-acting factors, in association with as yet 
undefined epigenetic changes, influence the balance of key osteoblast transcription 
factors, such as Runx2 and Osterix, relative to key chondrogenic transcription factors, 
such as Sox9.    
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Another secreted growth factor family that could play a role in regulating MSC fate 
determination in bone healing is the Wnt family (reviewed in (133)). In non-fracture 
environments, inhibiting beta-catenin activity in the osteoblast lineages leads to decreased 
bone mass and increased chondrogenesis (134-136), while ablation of Wnt inhibitors, DKK (137) 
or sclerostin (138), increases bone formation and bone mass. While the developmental role of 
canonical Wnt has been demonstrated, less is known about its role during fracture healing 
(133)
. In areas of intramembranous ossification in murine femur fractures, Dishevelled and 
beta-catenin have been localized to osteoblasts lining regions of newly formed woven bone 
and in those destined to be trapped in new bone (139). Fracture studies in Wnt deficient mice 
suggest impaired healing compared to wild type littermates (140, 141), likely as a result of 
disturbed osteoblast function since cartilage formation and osteoclasts numbers degrading the 
mineralized matrix are unaltered in its absence (142). Conversely, mice deficient in Sclerostin 
(an inhibitor of the canonical Wnt/beta-atenin pathway) heal single cortical, fully stabilized 
mid-diaphyseal femur fractures more robustly than wild type mice (143). This is in large part 
due to increased osteoblast numbers and bone surfaces 7-14 days post-injury. Importantly, a 
therapeutic benefit to fracture healing has been shown when canonical Wnt signaling was 
stimulated by adding a monoclonal antibody to the Wnt inhibitor DKK (144, 145).  
 
Intramembranous ossification - osteoblasts 
 
Direct differentiation of mesenchymal progenitors to osteoblasts is the exclusive mechanism 
of bone repair in fully stabilized defects (intramembranous ossification), but also occurs 
along the periosteal and endosteal surfaces of the bone in less stabilized fractures. (Figures 
1E, 2B and 4) Periosteal progenitor cells appear to have a bi-potent osteo-chondral potential, 
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with differentiation linked to the mechanical microenvironment, as detailed previously. 
Osteogenic differentiation of the periosteal MSC gives rise to intramembranous bone locally 
along the bone surfaces adjacent to the fracture; while these same periosteal progenitor cells 
migrate into the fracture gap to undergo chondrogenesis. In contrast, endosteal stem cells 
exhibit uni-potent osteogenic potential. Intramembranous bone formation from these 
endosteal stem cells is thus responsible for rapidly bridging across the marrow cavity (97).  
 
Endochondral bone formation – chondrocytes  
Temporally, chondrogenic differentiation of fracture callus progenitor cells is closely 
aligned with resolution of the pro-inflammatory response and occurs on the fibrin 
scaffold that was generated as part of the hematoma. Spatially chondrogenesis occurs 
primarily in the fracture gap, with periosteal stem cells being the primary source of the 
chondrocytes (146). (Figure 1E, 2B and 4) 
 
Following initial fate specification of the MSC to a chondrocyte, SOX9 expression plays 
an essential role in maintaining the cartilaginous phenotype and hypertrophic maturation 
(147-149)
. SOX9, along with transcriptional co-factors SOX5 and SOX6, regulate the 
expression of collagen II (150-152) and aggrecan (153). These are the canonical extracellular 
matrix proteins of cartilage, and together make up ~90% of the dry weight of the tissue, 
imparting cartilage with its characteristic biophysical properties. This dense cartilage 
callus bridges the fracture gap and helps stabilize the defect. At this stage the cartilage 
tissue becomes avascular, repressing angiogenesis and vascular invasion (154).  
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Conversion of the cartilage callus to bone occurs following a highly regulated maturation 
of chondrocytes from a proliferative through a hypertrophic state (Figure 5)(2). 
Hypertrophic maturation is distinguished morphologically by a dramatic increase in cell 
volume. Hypertrophic chondrocytes in the growth plate increase in size ~20-fold by 
taking on both volume and dry mass (155). At a molecular level, the hypertrophic 
chondrocyte is distinguished by the expression of collagen type X. While the exact 
function of collagen X is not clear, it is uniquely expressed by hypertrophic chondrocytes 
and matrix deposition is believed critical in priming the matrix for mineralization.  
 
Chondrocyte hypertrophy represents a pivotal state during endochondral ossification. 
Hypertrophic chondrocytes are highly angiogenic and facilitate a second phase of 
vascular invasion into the cartilage callus by synthesizing VEGF (156-158), PDGF (platelet 
derived growth factor) (159), and PlGF (placental growth factor) (160). Adjacent to the 
invading vasculature, hypertrophic chondrocytes lose Sox9 expression, which 
subsequently relieves repression of osteogenic promoters Runx2 and beta-catenin (2, 147). 
Subsequently, hypertrophic chondrocytes begin to express canonical markers of bone, 
including, alkaline phosphatase, osterix, osteopontin, and osteocalcin (161). Together, 
activation of osteogenic programs and angiogenesis result in calcification of the cartilage 
matrix (162). From a functional perspective this calcification provides additional rigidity to 
the fracture.   
 
The molecular trigger for calcification is not completely clear, but BMPs likely play a 
key role in this process. BMP are expressed by both hypertrophic chondrocytes (132) and 
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vascular endothelial cells (163), suggesting that there are both cell-autonomous and 
paracrine effects of BMP signaling that may drive calcification. Invasion of the 
vasculature also provides hypertrophic chondrocytes with other systemic factors such as 
extracellular calcium, parathyroid hormone, vitamin D, and insulin-like growth factor 
that play a role in controlling mineral homeostasis during fracture repair. Whether it is 
BMP expression alone from the vascular endothelial cells that drives calcification of the 
cartilage, or whether additional secreted factors (164) may also contribute to this process 
remains unclear.  
 
Following calcification of the cartilage, bone formation occurs. In this vascularized 
transition zone between cartilage and bone, histological staining reveals hypertrophic 
chondrocytes entrapped in a bone matrix adjacent to the vasculature (2). As cartilaginous 
matrix is lost and bone matrix is laid down the large round hypertrophic morphology of 
chondrocytes is gradually converted into morphology characteristic of the osteocytes with 
cellular extensions existing in canaliculi. How this shape change is facilitated remains an 
outstanding question, but reductive cell division of the hypertrophic chondrocytes may be 
one mechanism enabling this morphogenesis (2). Similarly, the mechanism by which the 
cartilage matrix is degraded remains debated and will be discussed later.  
 
The ultimate fate of the hypertrophic chondrocyte at the time of bone formation has 
recently been redefined both in the growth plate and fracture callus (Figures 2 and 5). 
The traditional model held that hypertrophic chondrocytes were a terminally 
differentiated, post-mitotic cell, fated for apoptosis. According to this model, new bone 
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was formed by osteoprogenitors or pre-osteoblasts that invade acellular cartilage matrix 
along with the vasculature (165). This dogmatic view of cell death in the hypertrophic 
chondrocyte overshadowed early work suggesting that chondrocytes could directly give 
rise to bone during endochondral ossification (166-169). However, more recently a number 
of genetic lineage tracing studies using chondrocyte-specific, temporally-regulatable 
promoters (Table S2) have clearly demonstrated that chondrocytes live and differentiate 
to become osteocytes both in the growth plate during development and during fracture 
repair (164, 170, 171) (2) (Figure 5). 
 
The mechanism by which chondrocytes transform into osteocytes remains poorly 
defined, but a few possibilities have been proposed. The osteocyte could just be the 
terminal fate of the chondrocyte, representing the natural phenotypic progression of these 
cells during maturation; or the chondrocyte could de-differentiate to a progenitor-like 
state prior to activating the osteoblast programs, and then becoming an osteoblast (2, 164, 
172)
. Another proposed mechanism is that the hypertrophic chondrocytes undergo an 
asymmetric cell division, at which point one of the daughter cells becomes an 
osteoblast/osteocyte and the other undergoes apoptosis (173-175). These suggested pathways 
are not mutually exclusive. For example, activation of the stem cell genes may not truly 
impart multipotency, but rather reactivate the cell cycle or enable the chromatin 
remodeling required for osteoblast gene expression. Significantly more work is required 
to understand the molecular details that regulate conversion of hypertrophic chondrocytes 
to osteoblasts, and to understand how chondrogenic matrix is converted to an osteogenic 
matrix.  
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It should be noted, that some amount of apoptosis of hypertrophic chondrocytes and 
osteoblasts/cytes is required to create marrow space. Similarly, evidence suggests that in 
the growth plate at least some of the endochondral bone is formed by osteoblasts (165). 
Consequently, it is important to recognize that this new model does not exclude the 
possibility that chondrocyte apoptosis and invading osteoblasts contribute to the newly 
formed bone at the fracture site. Determining the contribution of the various cell sources 
will require more study utilizing cell-type-specific temporally-regulated Cre-based 
studies.  
 
Callus Remodeling and Osteoclasts 
Remodeling of the bony callus is traditionally considered the last stage of fracture repair. 
Remodeling must occur to degrade the provisional bone that is first produced, referred to as 
woven bone, and replace it with mature lamellar bone. A key component of callus 
remodeling is bone degradation by osteoclasts (176) (Figure 1F and 2). Osteoclasts are 
myeloid lineage multinucleated cells that form tight attachments to the bone surface via a 
specialized membrane structure called the sealing zone (177). Vesicle trafficking delivers both 
soluble and membrane-bound lysosomal proteins to the sealing zone, and fusion of these 
transport vesicles with the intra-sealing zone plasma membrane creates the high-surface-area, 
manifold ruffled border that is the hallmark of a mature resorbing osteoclast (178-180). The 
acidic pH of Howship’s lacuna facilitates dissolution of hydroxyapatite crystals comprising 
the mineral component of bone while proteases digest the underlying collagenous matrix. 
Osteoclast mediated degradation of the bone liberates bone-sequestered factors, such as TGF-
beta as well as factors produced by the osteoclast itself, such as complement 3a, Wnt10b, 
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BMP6, and SLIT3 (181, 182) which are hypothesized to be critical in the subsequent stimulation 
of osteogenesis (183, 184). Resorption is concluded with the apoptotic death of the osteoclast, an 
event that can be stimulated by the hormone calcitonin or 17-beta-estradiol-enhanced Fas 
ligand expression (185).  
 
Osteoclasts originate from hematopoietic monocyte/macrophage lineage precursors. 
Proliferation and survival of osteoclast precursors is stimulated by interaction between 
monocyte/macrophage colony-stimulating factor (MCSF) and its receptor c-fms, which is 
present on both macrophages and osteoclasts. Bone marrow macrophages differentiate 
into osteoclasts upon stimulation with Receptor Activator of Nuclear Factor kappaB 
Ligand (RANKL) which binds to its receptor, RANK (186).  Osteoclast differentiation 
occurs through multiple phases. (176, 187). Both MCSF and RANKL are required 
throughout the differentiation process and also contribute to the survival of mature 
osteoclasts. MCSF and RANKL are both necessary and sufficient for osteoclast 
formation and function, but multiple other cytokines and signaling pathways influence 
osteoclast differentiation, maturation, and survival (188-191).  
 
Both RANK and RANKL knockout mice have demonstrated the critical role of 
osteoclasts in physiological bone remodeling, but the role of osteoclasts in fracture repair 
has been investigated only recently (192, 193). The medaka fin ray fracture model has 
allowed for longitudinal observation of the cellular contribution to fracture repair and has 
revealed a role for osteoclasts in two stages (194). Following the inflammatory phase of 
fracture, osteoclasts are recruited to smaller bone fragments which are partially resorbed. 
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This partial resorption deburrs the edges of the fragments which are later incorporated 
into the callus, but whether osteoclast resorption of the fragments is necessary for their 
preservation in the growing fracture callus is unknown. Osteoclast activity is again 
induced near the conclusion of the healing process, wherein they remodel the hard callus 
and restore the bone to dimensions similar to those prior to injury. Inhibition of osteoclast 
protease activity using cathepsin K inhibitors during the bony callus remodeling phase 
results in calluses with greater mineral density, but also increases osteoclast surface and 
osteoblast numbers (195). Pharmacological disruption of osteoclastogenesis by inhibiting 
transient receptor potential cation channel subfamily V member 1 (TRPV1) has been 
used as a treatment strategy for post-menopausal bone loss. However, fracture studies 
using TRPV1 knockout mice demonstrated an essential role of osteoclasts in soft-callus 
formation and remodeling (196). The decreased osteoclast number in TRPV1 mice lead to 
enlarged malformed calluses and persistent fracture gaps. In addition, there was down 
regulation of RUNX2 and ALP in MSCs.  
 
Remodeling during the process of endochondral bone formation is also necessary; 
however, the requirement for osteoclasts in this process are less-clear. Osteoclasts can be 
detected in histological sections of the endochondral callus and therefore are sometimes 
referred to as chondroclasts (though there is no evidence that these are a cell type distinct 
from osteoclasts). While osteoclasts are capable of resorbing cartilage, it is not clear that 
they have a functional role. Both human and animal studies have revealed that inhibiting 
osteoclast function does not significantly impact remodeling of the cartilaginous callus, 
but will delay bony callus remodeling (197-200).  
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If not mediated through direct interaction with osteoclasts, degradation of the cartilage 
callus may be accomplished indirectly through other cells expressing MMPs. As 
discussed earlier, MMPs are a family of extracellular matrix proteins with a demonstrated 
functional role in fracture repair. MMPs are expressed by many of the cells involved in 
bone healing, including osteoblasts and chondrocytes, and have differential specificity 
towards the collagens and proteoglycans found in the cartilage matrix. MMP13 has high 
specificity towards both collagen II and aggrecan and is made by both hypertrophic 
chondrocytes and osteoblasts. Similarly MMP9, with specificity towards gelatin (or 
degraded collagen), is made by both vascular endothelial cells and macrophages (84, 201). 
Interestingly, transplantation of wild type bone marrow into MMP9 mutants rescues the 
remodeling defect that is observed in the mutant animals (83), but this same experiment 
does not rescue the remodeling defect in the MMP13 mutant (81). These outcomes suggest 
that MMP9 expressed by cells derived from the hematopoietic system and MMP13 
derived from the chondrocytes work in concert to remove cartilage during endochondral 
ossification.  
 
Conclusions 
 
While we have discretely discussed the various phases of healing, the reality is that there 
is overlap of all phases of healing.  This spatiotemporal heterogeneity of fracture healing 
has made studies of fracture cell biology challenging. However, the utilization of 
genetically modified mice has permitted a more rapid advancement in our understanding 
of the cells involved in fracture repair (Table S2). Cell-specific reporter mice have 
permitted us to prospectively identify the cells of the callus to provide spatial resolution. 
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The development of tissue-specific promoters driving inducible Cre-activity enables 
additional temporal resolution for lineage tracing. Indeed, it was only relatively recently 
that the periosteal and endosteal origin of mesenchymal cells was definitively determined 
based on promoter reporter lineage tracing. Similarly, recent temporally defined lineage-
specific data from Bahney et al. has been able to demonstrate the transdifferentiation of 
chondrocytes to osteoblasts (2).  Traditional gene knockouts as well as tissue specific and 
temporally define knockout models have permitted us to understand gene function in the 
context of defined cell types. This has been particularly true for probing the role of BMP.  
Over the next decade, this temporally-regulated, cell-type specific gene regulation will 
permit a more careful dissection of fracture cell biology. The next frontier will be to 
understand how multiple cell types and resultant signaling networks are integrated 
spatially over time to regulate healing.   More advanced computational models of cellular 
behavior in complex environments will be useful for understanding these influences. 
From a translational perspective, advances in understanding the cell biology of fracture 
will then need to be extended to larger animal models, and to pathological fracture 
healing.   
Figure Legends 
Figure 1.  Fracture healing is temporally-defined process. (A) At injury there is 
disruption of periosteum and bone (B) A clot forms immediately providing a provisional 
matrix. Platelet degranulation releases chemokines to recruit inflammation. (C) 
Inflammatory phase leads to a period of (D) Mesenchymal expansion and migration from 
the periosteum and endosteum and angiogenesis, (E) Bone is formed via both 
endochondral (round cells) and intramembranous ossification (cuboidal cells), (F) 
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Osteoclasts (multinucleated cells) resorb primary bone and the process of remodeling 
restores bone shape and structure 
 
Figure 2.  Multiple cell-types present during the process of bone regeneration.  Tibae 
were harvested 5 (A), 10 (B), and 20 (C) days post closed fracture and fixation with an 
intramedullary pin. Longitudinal histological sections were stained with H&E (A) or 
safranin-o (B and C) imaged at 2.5X and images stiched together and higher 
magnification images at 20X, 40X, and 100X obtained.  (A) 5 day post-fracture 
undifferentiated mesenchymal cells are present in the callus and areas of inflammation 
remain (boxed area in 40X image is magnified in 100X) EC=endothelial cell; 
N=neutrophil; L=lymphocyte; M=macrophage.  (B) 10 days post-fracture there is both 
endochondral ossification (red staining, safranin-o stains cartilage) and intramembranous 
bone formation occurring. Boxed areas in 20X images are magnified in 40X images. 
EC=endothelial cell, PC=proliferation chondrocytes; HC=hypertrophic chondrocytes. 
OB=osteoblast.  (C) 20 days post-fracture.  An extensive network of primary bone has 
formed and endochondral ossification is complete.  Boxed areas in 20X images are 
magnified in 40X images.  Ob=Osteoblast; Ocl=Osteoclast; Ocy=osteocyte; 
Hcdo=hypertrophic chondrocyte derived osteoblast.  
 
Figure 3. Macrophage precursors develop into both classically activated and 
alternatively activated macrophages.  Monocyte precursors give rise to both the 
osteoclast lineage and to inflammatory macrophages.  Various factors, such as IFN-
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gamma, IL4, and IL13 control transitions between classically activated macrophages 
(CAM) and Alternatively activated macrophages (AAM).   
 
Figure 4.  Mesenchymal precursors develop into both osteoblasts and chondrocytes.  
Osteochondral progenitors are activated at the time of bone injury and a balance in 
transcriptional activation results in the cells becoming either osteoblasts or chondrocytes.  
Hypertrophic chondrocytes can differentiate to become osteoblasts.  
 
Figure 5.  Hypertrophic chondrocytes develop into osteoblasts and osteocytes.  
Tibiae were harvested post fracture and stained with (A) Safranin-O to define the 
chondrogenic front as outlined in panel (B).  (B) shows zones of hypertrophic 
chondrocytes, transition zone, Bone, and blood vessels (BV).  Pane C is a low 
magnification H&E image showing the localization of panels D and E in areas of bone.  
Cells of bone can be traced to the chondrocyte lineage using the (D) Col2CreERT2::Ai9 
or the (E) AgcCreERT::Ai9 mouse with a tamoxifen pulse.  
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